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Effects of recombinant human leukocyte interferon Q' AID on experimental myocarditis due to encephalomyecarditls virus were investigated. Plaque reduction assays revealed that 50% of plaque formation in vitro in human amnion (FL) cells was inhibited by interferon Q' AID (9.7 Vlml) when it was administered 24 hours before infection with the encephalomyocarditis virus. Four week old male DBAl2 mice were inoculated intraperitoneally with 10 plaque-forming units (pfu) of encephalomyocarditis virus. Interferon Q' AID was administered subcutaneously (10 2 U/g body weight per day in Group 1, 10 3 Ulg per day in Group 2 and 10 4 U/g per day in Group 3) starting 1 day before infection. It was also administered starting the same day in Group 4 and 1 day after virus inoculation in Group 5 (10 4 U/g per day in both groups). Control mice were injected with saline solution. Each group consisted of 10 mice; they were killed on day 4 for evaluation.
Interferon was discovered in 1957 by Isaacs and Lindemann (I) and has been found to comprise a family of proteins that share significant antiviral properties . Three major types of interferon are known to exist. These include alpha, beta and gamma interferons. Alpha interferon is generally produced when leukocytes are exposed to viruse s. Recombinant DNA technology has shown that as many as 12 Myocardial virus titers were significantly lower in Group 3 (8.2 ± 25.2 x 10 2 pfulmg, p < 0.05) and Group 4 (3.0 ± 5.5 x 103 pfu/mg, p <~.05) than in control mice (5.6 ± 4.1 x 10 4 pfu/mg). Histologic examination showed extensive myocardial necrosis and cellular infiltration in all control mice, but no myocardial necrosis or cellular infiltration in Group 3 and less severe necrosis and infiltration in Group 4. There were no significant differences in myocardial virus titers or histologic changes between control mice and Group I, 2 or 5.
Thus, interferon Q' AID, when administered starting before or simultaneously with virus inoculation, effectively inhibited myocardial virus replication and reduced the inflammatory response and myocardial damage in an experimental model of viral myocarditis. aAm CoIl Cardiol1987;9:1320-5) human alpha interferon genes and polypeptides exist in white blood cells (2) .
Natural human interferon preparations do not show significant activity in mouse cells . However, a recombinant human leukocyte interferon subtype aD and hybrid interferon a AID were shown to have relatively high antiviral activity in murine cell cultures and in vivo (3) . In our study we investigated the effect of recomb inant human leukocyte interferon a AID on experimental viral myocarditis, using a recently developed animal model (4, 5) .
Methods
Virus. The M variant of encephalomyocarditis virus was used . Virus stock was prepared as previously described (4) and stored at -70°C until diluted for use. Viral titers were determined by plaque formation on human amnion (FL) cell monolayers. Cells were suspended at a concentration of 1 x 10 6 in Eagle's minimal essential medium with 15% fetal calf serum plus 100 ILg/ml of pen-0735-I097/87/$3.50 Jane 1987: 1320-5 
1321
icillin and streptomycin in six-well plastic plates and were allowed to grow for 4 day s at 37°C in 5% carbon dioxide. Volumes (0.1 ml) of decim al dilutions of virus suspensions were adsorbed to FL cell monolayers for 60 minutes at 37°C in 5% carbon dioxide . After adsorption, the cell s were overlaid with 3 ml of med ium containin g 4% fetal calf serum and 1% methylcellulose . After 2 days of incubation at 37°C in a humid ified atmo sphere conta ining 5% carbon dioxide , cells were fixed with acetic acid and methanol (at a ratio of 1:3) and stained with crystal violet (I %), and plaque s were counted with an inverted micro scope .
In vitro assays of interferon. Recombin ant human leukoc yte interferon a AID was supplied by Hoffmann-La-Roche , Inc. Anti viral activit y of the drug in vitro was assayed by a plaque reduction method . Confluent monol ayers of FL cells in six-well plastic plates were treated with medium containing variou s con centrations of interferon a AID (0, 1, 10 or 100 U/ml ). Twenty-four hours later, cells were washed three time s with phosphate-buffered saline solution and were inoculated with 100 plaque-forming units (pfu) of enceph alomyocarditis viru s. After adsorption, the cells were overlaid as described earlier.
After 2 days of incubation at 3rC, cells were fixed with acetic acid methanol, stained with crystal violet and plaques were counted. Percent plaque formation was expressed as percent of plaques of untreated cont rols. The drug concentration requ ired to reduce the number of plaque s by 50% from the number in control wells (the median inhibitory dose , ID 50 ) was calculated from the graph relating plaque number and drug concentrations on a semilog plot (linear regression) (6) .
Treatment of cells with increasing concentrations of interf eron a AID resulted in progressive reduction of plaqu e fo rmation. The mean percent plaque formation was 110.8 % at an interferon a AID conc entration of I U/ml, 34 .6% at 10 U/ml and 3.7% at 100 U/ml (each n = 5). Thus a concentration of 10 U/ml of the drug was effective in reducing the number of plaques produced by the virus, and plaque formation was compl etely inhibited at 100 U/m!.
Linear regress ion anal ysis showed good negati ve correlation of y = 9 1.9 -48.5 10g lOx , r = -0 .938, P < 0 .001 , Virus titers of tis sues. For infectivity assays. tissues were removed asepti cally, weighed and homogenized in 2 ml of Eagle' s minim al esse ntial medium. After centrifu- gation at 1,500g for 15 minutes at 4°C, supernatants were inoculated into FL cell monolayers, and plaque assays were performed. Virus titers in the brain were investigated in Group 3 and control mice. Histopathology. The hearts were fixed in 10% formalin solution, embedded in paraffin and stained with hematoxylin-eosin. Myocardial cell necrosis, cellular infiltration and calcification were scored by observers who were unaware of other data on a scale of I + to 4 + in terms of severity as previously described (7) . A 1 + score described a limited focal distribution of myocardial lesions. A 4 + score indicated the presence of multiple lesions over the entire heart, whereas scores of 2 + and 3 + were used to describe intermediate lesion severity.
Statistics. The Kruskal-Wallis test was used to evaluate the difference between histologic gradings. Virus titers of the heart were examined by an analysis of variance followed by the Neuman-Keuls test for multiple sample comparison (8) .
Results
Mortality. None of the mice died before day 4. One control mouse, two mice in Group I, one in Group 2 and two in Group 5 died. No mice in Group 3 or4 died. Mortality was not an end point of our study.
Myocardial virus titer (Tables 1 and 2 ). The myocardial virus titer of the control group was 5.6 ± 4.1 X 10 4 pfu/mg (mean ± SD). Titers of treated groups were 7.1 ± 6.8 x 10 4 pfu/mg in Group 1, 6.2 ± 7.2 x 10 4 pfu/mg in Group 2, 8.2 ± 25.2 x 10 2 pfu/mg in Group 3, 3.0 ± 5.5 x 10 3 pfu/mg in Group 4 and 6.0 ± 6.3 x Virus titers in the brain. Virus titer in the brain in Group 3 was 4.5 ± 10.3 x 10 2 pfu/mg (range 0.\ to 3.3 x \0 3 ) and was significantly lowerthan that in control mice (1.8 ± 1.4 x 10 3 pfu/mg, range 3.4 X 10 2 to 4.5 X 10 3 , P < 0.05).
Histologic findings (Tables 3 and 4, Fig. 1) . Cellular infiltration and myocardial necrosis were found in all untreated hearts but were absent in all hearts of mice in Group 3 and in 6 of 10 hearts in Group 4. Cellular infiltration and myocardial necrosis were significantly less severe in Groups 3 and 4 than in other groups (p < O. a1). Myocardial calcification was found in the hearts of all untreated mice. in the hearts of half of the mice in Groups 2 and 3 and in 3 of 10 mice in Group 4. Myocardial calcification was less severe in Groups 3 and 4 (p < 0.05).
When treatment with interferon a: ND (10 4 U'g per day.
Group 3) was started before or simultaneously with virus inoculation, the inflammatory response and myocardial damage were effectively reduced. Representative photographs of the heartsof treated and untreated mice are shown in Figure I .
Discussion
Interferon treatment for viral diseases. Recombinant human leukocyte interferon is currently being tested in patients with cancer and viral diseases to assess its toxicity and therapeutic efficacy. Reported side effects includefever. chills, fatigue, anorexia. myalgias, nausea, vomiting, headaches, dose-dependent reversible leukopeniaand elevations of hepatic transaminase (9) (10) (11) . A placebo-controlled, double-blind randomized study ( 12) showed that treatment with low dose leukocyte alpha interferon markedly reduced symptomatic cytomegalovirus infection in kidney transplant PREVENTION OF VIRAL MYOCARDITIS WITH INTERFERON JACC Vol. 9. No.6
June 1987:1320-5 recipients. The use of recombinant alpha interferon for treatment of hairy cell leukemia in humans has received approval from the U.S. Food and Drug Administration. The side effects have usually been dose-related and in many cases may be managed successfully by the use of antipyretic agents such as acetaminophen or by reducing the dose of interferon. Studies are still underway to evaluate the role of interferon in the treatment of several human viral diseases. For shortterm use in acute illness such as myocarditis, interferon should be associated with minimal side effects.
Because interferon has multiple immunologic effects, it may contribute to the body's defense against various microbial assaults. However, it appears likely that interferon plays a significant role in the control of viral infections. This assumption has been supported by a number of studies that have suggested that neutralization of interferon using specific antisera enhances the severity of viral infection. Thus, Gresser et al. (13) demonstrated a role of interferon in the pathogenesis of encephalomyocarditis virus infection by treating mice with anti-mouse interferon globulin. In mice treated with anti-mouse interferon globulin, the virus was present in high titer in visceral organs and mice died more frequently and earlier than did untreated mice. Goeddel et al. (14) showed protective effects of recombinant interferon-oA against the lethal infection of squirrel monkeys with encephalomyocarditis virus.
Subtypes of interferon. Week et al. (3) investigated
recombinant human leukocyte interferon subtype aA, aB, aD and two hybrid interferons a AID and a DIA for in vivo and in vitro activity. A single intraperitoneal injection of 10 4 U of interferon-aD or a AID 3 hours before infection caused significant protection against lethal encephalomyocarditis virus infection of CD-I mice. Treatment with interferon-aA or a DIA did not cause significant protection against encephalomyocarditis virus infection. Repeated treatments with 10 2 , 10 3 or 10 4 U of interferon a AID caused greater protection than did single treatments at the same dose given 3 hours before infection. However, single or multiple treatments at or after 24 hours postinfection did not cause significant protection against encephalornyocarditis virus infection with any of the interferon preparations. Also, Giron and collaborators (IS) found that the production of diabetes by the D strain of the encephalomyocarditis virus was blocked by interferon-S, as well as by a variety of interferon inducers in SWR/J mice. Effects of interferon-a AID on the heart were not studied by these investigators. However, interferon-,Bhas been shown to inhibit replication of coxsackie virus B3 in cultured human heart cells (16) .
Viral myocarditis due to encephalomyocarditis virus.
This virus is a picornavirus biologically similar to coxsackie virus. It is periodically isolated in diagnostic and epidemiologic investigations as the etiologic agent of disease in domestic swine (17), captive wild animals or nonhuman primates (18) . Epizootic outbreaks of virus infection with this virus have been reported in swine, manifesting as severe and fatal myocarditis (19) .
In our study, in an animal model of viral myocarditis, we demonstrated that human leukocyte interferon a AID given I day before or simultaneously with inoculation with encephalomyocarditis virus inhibited multiplication of virus in the heart and protected mice from developing myocarditis. Prevention was dependent on dosage and on the time of initiation of treatment. When treatment was started before or simultaneously with virus inoculation, interferon a AID in a dose of 10 4 U/g per day effectively reduced the inflammatory response and myocardial damage. Myocardial calcification was less severe but was still seen in these groups. Because early calcification follows myocardial necrosis in this animal model (5, 7) , the focal calcification seen in these groups may be the sequel of less severe myocardial necrosis.
Current therapy for viral myocarditis is symptomatic and supportive, and specific treatment is not available. Recently, we demonstrated in an animal model that a broad-spectrum antiviral agent, ribavirin, protected mice from development of encephalomyocarditis virus myocarditis (7) . Mice treated with ribavirin survived longer than did control mice. Ribavirin inhibited encephalomyocarditis virus replication in the heart, and this inhibitory effect correlated well with the decrease in severity of myocardial damage and inflammatory cellular infiltration. However, because of failure of ribavirin to rapidly penetrate the blood-brain barrier, it did not inhibit viral replication in the brain, even in mice treated with high doses. In the present study, 10 4 U/g of interferon a AID started 1 day before infection significantly reduced viral replication in the brain. Therapeutic implications. Interferon is a broadly active antiviral agent and therefore should be of great advantage in treating diseases of multiple etiology, such as viral respiratory or viral gastrointestinal illnesses, as well as viral myocarditis. At first sight, the demonstrated beneficial effects of treatment with recombinant interferon-a AID before and at the time of virus inoculation may appear to be of little clinical value. However, clinical relevance may lie in the protection of individuals infected in the laboratory or exposed to epidemic outbreaks, such as those that occur among infants, in hospital nurseries (20) . We believe that our results justify further study of the effects of interferon a AID against other cardiotropic virus infections used with or without other therapeutic agents.
